Media headlines about Cyclacel Pharmaceuticals (NASDAQ:CYCCP) have been trending positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a daily sentiment score of 0.36 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.1203928998456 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Cyclacel Pharmaceuticals (CYCCP) remained flat at $6.11 on Friday. 1,000 shares of the company’s stock were exchanged. The stock’s market capitalization is $69.65 million. The company’s 50 day moving average price is $6.29 and its 200 day moving average price is $6.47. Cyclacel Pharmaceuticals has a 52 week low of $5.05 and a 52 week high of $9.05.
The company also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 14th were paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 9.82%. The ex-dividend date of this dividend was Wednesday, July 12th.
TRADEMARK VIOLATION WARNING: “Cyclacel Pharmaceuticals (CYCCP) Earning Positive News Coverage, Accern Reports” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://stocknewstimes.com/2017/08/19/cyclacel-pharmaceuticals-cyccp-receives-daily-news-sentiment-score-of-0-36-updated.html.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Ratings for Cyclacel Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
